From paper to predictive: a new era in drug development and compliance

Pharmaceutical regulatory processes are undergoing a significant transformation, largely driven by the integration of Artificial Intelligence (AI). What was once a slow, paper-intensive system is now evolving into a smarter, faster, and more predictive framework. This journal explores the shift from traditional methods to AI-powered tools that enhance various aspects of regulatory affairs, including regulatory submissions, safety monitoring, labeling, and compliance. While AI offers clear advantages—such as improved speed, accuracy, and efficiency—it also raises critical concerns regarding data privacy, fairness, and regulatory approval. These issues must be carefully considered to ensure that AI applications in regulatory processes remain transparent, unbiased, and compliant with established standards. This journal provides real-world insights and practical analyses, highlighting both the opportunities and challenges of AI in regulatory affairs. It emphasizes the need for responsible innovation that prioritizes patient safety and adheres to ethical practices. By exploring the potential of AI while acknowledging its limitations, this journal aims to guide the pharmaceutical industry toward an AI-enhanced regulatory future that balances technological progress with the highest standards of care.